E-LIB Suche - Ergebnisse für: Isorna, S.

1

801 TIME TO PROGRESSION SHOULD NOT BE USED TO INFER THE ULT..:

Studer, U.E. ; Whelan, P. ; Wimpissinger, F....
European Urology Supplements. 10 (2011) 2 - p. 253 , 2011

Link: https://doi.org/10.1016/..

2

804 IMMEDIATE OR DEFERRED ANDROGEN DEPRIVATION FOR PATIENTS..:

Studer, U.E. ; Whelan, P. ; Albrecht, W....
European Urology Supplements. 10 (2011) 2 - p. 254 , 2011

Link: https://doi.org/10.1016/..

3

PREDICTION OF RECURRENCE AND PROGRESSION OF NON- MUSCLE INV..:

Fernandez-Gomez, J.M. ; Madero, R. ; Solsona, E....
European Urology Supplements. 7 (2008) 3 - p. 298 , 2008

Link: https://doi.org/10.1016/..

4

19 WHICH SUBGROUPS OF PATIENTS WITH NEWLY DIAGNOSED TO-4 NO..:

Studer, U.E. ; Collette, L. ; Whelan, P....
European Urology Supplements. 6 (2007) 2 - p. 27 , 2007

Link: https://doi.org/10.1016/..

5

IS THE DEGREE OF PSA DECLINE AFTER IMMEDIATE ANDROGEN DEPRI..:

Collette, L. ; Studer, U.E. ; Whelan, P....
European Urology Supplements. 5 (2006) 2 - p. 288 , 2006

Link: https://doi.org/10.1016/..

6

PSA DOUBLING TIME AS PREDICTOR OF OBJECTIVE PROGRESSION AND..:

Collette, L. ; Studer, U.E. ; Whelan, P....
European Urology Supplements. 5 (2006) 2 - p. 203 , 2006

Link: https://doi.org/10.1016/..

7

WHICH PATIENTS WITH T0-4 N0 M0 PROSTATE CANCER NOT SUITABLE..:

Collette, L. ; Studer, U.E. ; Whelan, P....
European Urology Supplements. 5 (2006) 2 - p. 202 , 2006

Link: https://doi.org/10.1016/..

8

Comparison of Orthotopic Sigmoid and Ileal Neobladders: Con..:

Schrier, B.Ph. ; Laguna, M.P. ; van der Pal, F...
European Urology. 47 (2005) 5 - p. 679-685 , 2005

Link: https://doi.org/10.1016/..

9

303Patients with asymptomatic prostate cancer T.0-4 N.0-2 M..:

Studer, U.E. ; Whelan, P. ; Albrecht, W....
European Urology Supplements. 4 (2005) 3 - p. 78 , 2005

Link: https://doi.org/10.1016/..

10

Long-term follow-up of a randomized prospective trial compa..:

Martinez-Pineiro, J.A ; Flores, N ; Isorna, S...
Urologic Oncology: Seminars and Original Investigations. 21 (2003) 2 - p. 169-170 , 2003

Link: https://doi.org/10.1016/..

11

Quality of life after sigmond orhtotopic neobladder (short ..:

Laguna, P.M. ; Isorna, S. ; Belon...
European Urology Supplements. 2 (2003) 1 - p. 168 , 2003

Link: https://doi.org/10.1016/..

12

Comparison of a standard BCG dose (81 MG) versus a three-fo..:

Martinez-Piñeiro, J. ; Martinez-Piñeiro, L. ; Solsona, E....
European Urology Supplements. 2 (2003) 1 - p. 190 , 2003

Link: https://doi.org/10.1016/..

13

Long‐term follow‐up of a randomized prospective trial compa..:

Martínez‐Pin˜eiro, J.A. ; Flores, N. ; Isorna, S....
BJU International. 89 (2002) 7 - p. 671-680 , 2002

Link: https://doi.org/10.1046/..

14

Improving the Safety ofBCG Immunotherapy by DoseReduction:

Martinez-Pineiro, J.A. ; Solsona, E. ; Flores, N..
European Urology. 27 (1995) 1 - p. 13-18 , 1995

Link: https://doi.org/10.1159/..

15

Organization of the association cortical afferent connectio..:

Avendaño, C. ; Rausell, E. ; Perez‐Aguilar, D..
Journal of Comparative Neurology. 278 (1988) 1 - p. 1-33 , 1988

Link: https://doi.org/10.1002/..